Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy.
about
Tracking antigen-specific T-cells during clinical tolerance induction in humansT Cell Epitope Peptide Therapy for Allergic DiseasesStinging insect allergy: current perspectives on venom immunotherapyImmunoregulatory T cell epitope peptides: the new frontier in allergy therapyNew strategies for allergen T cell epitope identification: going beyond IgERecombinant allergens: the present and the futureImmunological mechanisms of allergen-specific immunotherapyTargeting allergen to Fc gammaRI: a strategy to treat allergic disease?Modulation of T cell function by combination of epitope specific and low dose anticytokine therapy controls autoimmune arthritis.Mechanisms of peptide immunotherapy in allergic airways disease.Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy.Synthesized OVA323-339MAP octamers mitigate OVA-induced airway inflammation by regulating Foxp3 T regulatory cellsProtective role of interleukin-10 in ozone-induced pulmonary inflammationInterleukin-10 promoter gene polymorphisms and susceptibility to asthma: a meta-analysis.Regulatory T cells in many flavors control asthmaNovel birch pollen specific immunotherapy formulation based on contiguous overlapping peptidesIn vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposureAllergy vaccines: dreams and reality.Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression.Effector and central memory T helper 2 cells respond differently to peptide immunotherapy.Interaction of allergens, major histocompatibility complex molecules, and T cell receptors: a 'ménage à trois' that opens new avenues for therapeutic intervention in type I allergy.Peptide immunotherapy for childhood allergy - addressing translational challenges.New directions in immunotherapy.Recombinant allergen immunotherapy: clinical evidence of efficacy--a review.Targeting IL-10 in auto-immune diseases.Current developments for improving efficacy of allergy vaccines.The efficiency of peptide immunotherapy for respiratory allergy.Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy.Penaeus monodon tropomyosin induces CD4 T-cell proliferation in shrimp-allergic patientsCombination peptide immunotherapy based on T-cell epitope mapping reduces allergen-specific IgE and eosinophilia in allergic airway inflammation.Blomia tropicalis allergen 5 (Blo t 5) T-cell epitopes and their ability to suppress the allergic immune response.Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract.Defining the T cell antigen proteome of wasp venom.Immunotherapy with allergen peptides.Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens.Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study.Bee venom inhibits hepatic fibrosis through suppression of pro-fibrogenic cytokine expression.Effects of bee venom treatment on growth performance of young pigs.T cell epitope immunotherapy ameliorates allergic responses in a murine model of shrimp allergy.
P2860
Q24320083-4D4CC5BB-D464-45AE-B8DC-E04490BAC47DQ26771989-4742C800-4146-4416-8A97-A6C65F51AEC4Q26801123-30291265-31F4-4B2E-9CB8-9AE8287C9C45Q26822702-C77EB014-5239-4556-ABB6-9727E73A2396Q26824787-DB16EC67-853A-4C94-A0D3-F499C22931C4Q26996701-0C0B7968-FF08-4E97-8605-421B0E6FC3DCQ28265326-9353B5BD-C641-4034-BE35-3FA47E5F1CB0Q30437725-F9376C9E-A224-4D63-9692-02DD56DE5A44Q33267344-62887D35-5CA3-43F5-9B3B-726673A84756Q33807395-940808D9-8533-4024-92D0-BD59274FC807Q34205503-69301D1E-4278-4D79-AC35-1F6F4E1F85E9Q34329409-508276C2-2072-4725-8E96-32C8F57EB156Q34407484-A680BD1C-1A87-4EF7-9BDA-95F77D187443Q34555743-ABE1F89E-ADFC-4607-8D56-79E86318C250Q34574231-F21ED4F9-E45D-4A56-BA36-6241A8B137C6Q36901292-1FB180FB-D239-4C35-8275-2846096FC909Q36979997-0EDDC749-2B2A-43EC-9255-573FD934AC4CQ37123463-C7FA7AAD-3785-4776-AE0F-C14AD67CBA0EQ37273245-1212F89B-80CF-477B-9C8D-D5EC83DF6EABQ37612747-F53890B7-11F9-47BA-964C-C9C7C311F605Q37859218-4EF7825E-BA1A-4CEE-AE30-1D2697C8ED17Q37992746-60C55026-EC0E-467F-8CAA-A5EE021075D5Q38073718-1EB8C39D-C652-435E-AF62-D658581AB72EQ38112352-154A1681-194D-4CE2-97F1-1BD785A69A69Q38196752-3C2FA070-0383-4882-9B53-952D622BF78DQ38503330-81CB5071-1C0F-4BA5-9D38-72FB0BF2150FQ38744223-3516F6A4-B5BE-4AD8-B9EA-6B1D920C9E4FQ39321330-6568B2A0-3174-416F-8ADD-0261C37DCA25Q39412480-9609F219-6C06-4F29-85FB-A942F030FE2CQ39527744-AA367CF3-B970-4714-8FFA-4C92D8B34A1EQ39601232-C55AD62B-F34C-40C1-8C88-96D928DEF0A3Q40023867-69F8D0E0-388F-462F-9573-9F99F62C65E7Q40087434-F6EBA75B-AC53-4068-926C-30EF6D99F88EQ40282948-42EDCB0D-AED5-4DD2-BA24-7739F1C0FAF4Q40657944-2BC00A83-DFC1-4916-B5CA-B5EA59C9AE9CQ41196294-EB91B133-CA98-44DB-96F9-809C19CAEFBDQ42631175-9FCD5BA9-8673-4A48-B619-826BCFFBF069Q42915317-1ECA20B6-CADD-43BC-BA9E-7A6118D9051FQ45977212-39367545-4E2D-4BFE-B566-ECA793646848Q46198561-3471A7F7-47EB-439F-AC35-FE1C210F7DDE
P2860
Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Induction of interleukin-10 an ...... llowing peptide immunotherapy.
@en
Induction of interleukin-10 an ...... llowing peptide immunotherapy.
@nl
type
label
Induction of interleukin-10 an ...... llowing peptide immunotherapy.
@en
Induction of interleukin-10 an ...... llowing peptide immunotherapy.
@nl
prefLabel
Induction of interleukin-10 an ...... llowing peptide immunotherapy.
@en
Induction of interleukin-10 an ...... llowing peptide immunotherapy.
@nl
P2093
P2860
P1476
Induction of interleukin-10 an ...... llowing peptide immunotherapy.
@en
P2093
B Maillere
S O Stapel
P2860
P304
P356
10.1111/J.1365-2222.2006.02469.X
P577
2006-04-01T00:00:00Z